Anticoagulants Market accounted 26837.4 million USD in 2020 and is expected to reach 55312.7 million USD by 2030 with a CAGR of 7.5% approximately during the forecast period. Anticoagulants medicine is also known as blood thinners drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in the heart, veins or arteries. The formation of clots in the blood can lead to a heart attack or stroke. These drugs are used to treat myocardial infarctions, strokes, pulmonary embolisms, deep vein thrombosis (DVT), and disseminated intravascular coagulation (DIC). The most commonly prescribed anticoagulant is Warfarin and is prescribed to people who are at a higher risk of getting clots. Warfarin and other alternatives are taken as capsules or tablets. Heparin is an anticoagulant that can be given by injection. The most popular types of anticoagulants are novel oral anticoagulants (NOACs), Vitamin K antagonists, and Low-molecular-weight heparin (LMWH). Novel oral anticoagulants (NOACs) have gained immense popularity in recent years due to their multiple benefits. Vitamin K antagonists are prescribed for prolonged anticoagulation therapy. Low-molecular-weight heparin (LMWH) enables outpatient management of disorders, such as pulmonary embolism, deep vein thrombosis, and others.  

Market Segmentation:

The global anticoagulants market is segmented by drug class into betrixaban, dabigatran (Pradaxa), edoxaban, rivaroxaban (Xarelto), eliquis (apixaban), NOACs, heparin & lmwh, vitamin k antagonist, and others.  By route of administration the market is divided into injectable anticoagulant and oral anticoagulant. By application the market is categorized into cardiovascular diseases, coronary artery diseases, cardiac arrhythmia, myocardial infarction, DVT, heart valve replacement, stroke, atrial fibrillation, pulmonary embolism (PE), and deep vein thrombosis (DVT)). By geography, the market is bifurcated into North America, Asia Pacific, Europe, and RoW. 

Market Dynamics and Factors:

The growing incidences of cardiovascular disorders, chronic diseases, and venous thromboembolism (VTE), increasing acceptance of novel oral anticoagulants (NOACs), growing awareness regarding the use of NOACs, escalating aging population, lack of precise substitutes for anticoagulant drugs, advantageous government policies, and rising number of obese people are the major factors driving the market. However, the high cost of NOACs, the existence of alternative drugs, stringent government regulations, side-effect risks, and complications related to the use of oral anticoagulants are restricting the growth if global anticoagulants market. Also, increasing investment in R&D in the pharmaceutical sector and the introduction of innovative oral anticoagulant drugs are expected to increase the growth of the market in the future. Stringent regulations implemented by many governments for health safety reasons will be a challenge in the growth of the global anticoagulants market in the short and medium-term.

Geographic Analysis:

North America dominates the global anticoagulants market and will lead the global anticoagulants market over the forecast time period, owing to the presence of state-of-the-art healthcare setup, high demand for innovative therapeutics, huge target population, the existence of trained healthcare professionals, and rising incidences of cardiovascular disorders. Europe will be the second-largest market for anticoagulants in the years ahead, due to the escalating aging population, rising occurrences of chronic diseases, advantageous government policies, and the rising number of obese people. The Asia Pacific will grow at a speedy rate over the forecast time period, owing to the huge population, growing number of people suffering from chronic disorders, such as cancer, diabetes, and cardiovascular diseases, promising government policies, and growing investments made by pharmaceutical companies for research and development.

Competitive Scenario:

The major players of the global anticoagulant market are Bayer AG, Aspen Holdings, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Inc., Sanofi S.A., Johnson & Johnson, and Portola Pharmaceuticals, Inc.

Anticoagulants Market Report Scope